DRUG - Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc. , a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
As of Jul 15, 2026: spot at $75.60, ATM IV 82.2%, max pain $60.00, net GEX $6.7K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $589.3M
- Beta
- 0.10
- 52-Week Range
- 24-123.75
- CEO
- Ian McDonald
- Employees
- 26
- IPO Date
- Mar 22, 2021
- Exchange
- NASDAQ
What DRUG Looks Like to Options Traders Today
positive net gamma exposure ($6.7K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.076) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The DRUG overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked DRUG overview questions
- What is DRUG?
- DRUG is the ticker symbol for Bright Minds Biosciences Inc., a listed security. Bright Minds Biosciences Inc. , a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Listed on NASDAQ. DRUG is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the DRUG options snapshot look like today?
- As of Jul 15, 2026, the DRUG options snapshot shows spot at $75.60, ATM IV 82.2%, max pain $60.00, net GEX $6.7K, expected move 23.57%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are DRUG's key statistics?
- Bright Minds Biosciences Inc. (DRUG) carries a market capitalization of $589.3M, beta of 0.10 relative to the broader market, 52-week range of 24-123.75. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does DRUG belong to?
- Bright Minds Biosciences Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare DRUG's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the DRUG data on this page?
- The options snapshot above is dated Jul 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).